abstract |
The present invention generally relates to an antibody that specifically binds to a programmed cell death protein 1 (PD-1), an activatable antibody that specifically binds to PD-1, and an anti-PD-1 antibody and anti-PD- Methods of making antibodies and methods of use in various therapeutic, diagnostic and prophylactic indications. |